长链非编码 RNA 在复发性卵巢癌中的作用：治疗和诊断新视角。
Long non-coding RNAs in recurrent ovarian cancer: Theranostic perspectives.
机构信息
Tsinghua Berkeley Shenzhen Institute, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, 518055, PR China.
Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China, Hefei, 230000, Anhui, PR China; The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, 230000, Anhui, PR China.
出版信息
Cancer Lett. 2021 Apr 1;502:97-107. doi: 10.1016/j.canlet.2020.12.042. Epub 2021 Jan 8.
Nearly 70% of ovarian cancer (OC) patients experience recurrence within the first 2 years after initial treatment. Emerging evidence indicates that long non-coding RNAs (lncRNAs) play a pivotal role in the pathogenesis of OC progression, resistance to therapy and recurrent OC (ROC). Transcriptome profiling studies have reported differential expression patterns of lncRNAs in OC which are related to increased cell invasion, metastasis and drug resistance. In this review, we highlighted the roles of lncRNAs in OC progression and outlined the potential molecular mechanisms by which lncRNAs impact on ROC. Recent advances using lncRNAs as potential biomarkers for screening, detection, prediction, response to therapy and as therapeutic targets are discussed.
近 70%的卵巢癌（OC）患者在初始治疗后 2 年内复发。新出现的证据表明，长链非编码 RNA（lncRNA）在 OC 进展、对治疗的耐药性和复发性 OC（ROC）的发病机制中起关键作用。转录组谱分析研究报告了 lncRNA 在 OC 中的差异表达模式，这些模式与细胞侵袭、转移和耐药性增加有关。在这篇综述中，我们强调了 lncRNA 在 OC 进展中的作用，并概述了 lncRNA 影响 ROC 的潜在分子机制。讨论了最近利用 lncRNA 作为筛查、检测、预测、对治疗的反应和作为治疗靶点的潜在生物标志物的进展。
Zotero 插件